In a research report issued today, Needham analyst Alan Carr reiterated a Buy rating on Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) and reduced the price target to …
In a research report issued today, Needham analyst Alan Carr reiterated a Buy rating on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with a $40 price target, after …
H.C.
